JOLTS Job Openings (Jun) 7.44M vs 7.5M Expected
Investing.com - Bernstein SocGen Group raised its price target on Edwards Lifesciences (NYSE:EW) to $85.00 from $80.00 on Monday, while maintaining a Market Perform rating on the medical device maker’s stock. The stock, currently trading at $79.58, is approaching its 52-week high of $83.00, with InvestingPro data showing the company maintains a strong financial health score of 2.87 (GOOD).
The price target increase follows Edwards Lifesciences’ second-quarter performance, which showed 10.6% organic growth, exceeding consensus estimates by 3% with stronger-than-expected results across all business segments. The company’s impressive 78.87% gross profit margin and $46.84B market capitalization reflect its strong market position. According to InvestingPro, there are 10+ additional insights available for subscribers, including valuable metrics on valuation and growth potential.
The company’s transcatheter aortic valve replacement (TAVR) business beat expectations by 3%, while its transcatheter mitral and tricuspid therapies (TMTT) and Surgical segments outperformed by 4% and 2.5%, respectively.
Edwards Lifesciences reported adjusted earnings per share of $0.67, surpassing consensus estimates by 7%, marking a significant improvement after five consecutive quarters with organic growth below 10%.
Bernstein increased its forward earnings per share estimate to $2.88 from $2.79 and raised its price-to-earnings multiple to 29.5x from 28.5x, citing the company’s improving growth trajectory, though the firm expressed lingering concerns about long-term TAVR data and TMTT growth trajectory.
In other recent news, Edwards Lifesciences reported strong financial results for the second quarter of 2025, with earnings per share (EPS) of $0.67, surpassing the forecast of $0.62. The company achieved revenue of $1.53 billion, exceeding the anticipated $1.49 billion. This performance was highlighted by a 7.8% year-over-year growth in its worldwide Transcatheter Aortic Valve Replacement (TAVR) business, excluding foreign exchange impacts. UBS raised its price target for Edwards Lifesciences to $85, citing strong sales in the TAVR and Transcatheter Mitral and Tricuspid Therapies (TMTT) segments. Piper Sandler increased its price target to $90, maintaining an Overweight rating, following the company’s better-than-expected second-quarter results. TD Cowen also lifted its price target to $84, noting the company’s strong performance and positive revisions to its full-year guidance. RBC Capital raised its price target to $89, maintaining an Outperform rating, and highlighted the double-digit revenue growth for the first time in over a year. These developments reflect a positive outlook for Edwards Lifesciences among analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.